Chapter 024

Antiarrhythmic Drugs

Frank J. Dowd

CITED REFERENCES

  1. Bigger JT, Breithardt G, Brown AM, et al: The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology, Circulation 84:1831-1851, 1991. PUBMED Abstract
  2. Drugs for cardiac arrhythmias, Treatment guidelines, Med Lett Drugs Ther 5:51-58, 2007.
  3. Drvota V, Blange I, Häggblad J, et al: Desethylamiodarone prolongation of cardiac repolarization is dependent on gene expression: a novel antiarrhythmic mechanism, J Cardiovasc Pharmacol 32:654-661, 1998. PUBMED Abstract
  4. Echt DS, Liebson PR, Mitchell LB, et al: CAST investigators: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial, N Engl J Med 324:781-788, 1991. PUBMED Abstract
  5. Goldstein RN, Stambler BS: New antiarrhythmic drugs for prevention of atrial fibrillation. Prog Cardiovasc Dis, 48:193-208, 2005. PUBMED Abstract
  6. Lee KS, Lee EW: Ionic mechanism of ibutilide in human atrium: evidence for a drug-induced Na+ current through a nifedipine inhibited inward channel, J Pharmacol Exp Ther 286:9-22, 1998. PUBMED Abstract
  7. Lombardi F, Terranova P: Pharmacological treatment of atrial fibrillation: mechanisms of action and efficacy of class III drugs, Curr Med Chem 13:1635-1653, 2006. PUBMED Abstract
  8. McClellan KJ, Markham A: Dofetilide: a review of its use in atrial fibrillation and atrial flutter, Drugs 58:1043-1059, 1999.
  9. Pitsiavas V, Smerdely P, Boyages SC: Amiodarone compared with iodine exhibits a potent and persistent inhibitory effect on TSH-stimulated cAMP production in vitro: a possible mechanism to explain amiodarone-induced hypothyroidism, Eur J Endocrinol 140:241-249, 1999. PUBMED Abstract
  10. Roden DM: Drug-Induce prolongation of the QT interval, N Engl J Med 350:1013-1022, 2004. PUBMED Abstract
  11. Shinagawa K, Shiroshita-Takeshita A, Schram G, et al: Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone, Circulation 107:1440-1446, 2003. PUBMED Abstract
  12. Singh BN, Singh, SN, Reda DJ, et al: for the Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) investigators: Amiodarone versus sotalol for atrial fibrillation, N Engl J Med 352:1861-1872, 2005. PUBMED Abstract
  13. Tomargo J, Caballero R, Gómez R, et al: Pharmacology of cardiac potassium channels, Cardiovasc Res 62:9-33, 2004.
  14. Vaughan EM, Williams DM: Classification of antidysrhythmic drugs, Pharmacol Ther [B] 1:115-138, 1975. PUBMED Abstract
  15. Wenckebach KF, Winterberg H, editors: Die unregelmässige herztätigkeit, Leipzig, 1927, W Engelmann.
  16. Yamreudeewong W, DeBisschop M, Martin LG, et al: Potentially significant drug interactions of class III antiarrythmic drugs, Drug Saf 26:421-438, 2003. PUBMED Abstract

GENERAL REFERENCES

  1. Darbar D, Roden DM: Future of antiarrythmic drugs, Curr Opin Cardiol 21:361-367, 2006 PUBMED Abstract
  2. Fogoros RN: Antiarrhythmic drugs: a practical guide, ed 2, Malden, Mass, 2007, Blackwell.
  3. Kass RS, Clancy CE, editors: Basis and treatment of cardiac arrhythmias. In Handbook of experimental pharmacology, Berlin, 2006, Springer.